The Sanford-Burnham Medical Research Institute and Pfizer agreed to collaborate in the discovery of new therapeutic targets for drugs that could treat and prevent complications related to diabetes and obesity. As part of the three-year deal, researchers will use Sanford-Burnham's systems biology expertise and screening technologies to identify strategies to address insulin resistance.

Related Summaries